期刊文献+

SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis 被引量:2

SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis
下载PDF
导出
摘要 AIM: To assess the influence of SLIT and NTRKlike family member 3(SLITRK3) on the prognosis of gastrointestinal stromal tumor(GIST) and determine whether SLITRK3 can help improve current risk stratification systems.METHODS: We hypothesized that SLITRK3 could be used as a prognostic molecular biomarker for GIST. 35 fresh tumor samples and 417 paraffin-embedded specimens from GIST patients were utilized. SLITRK3m RNA expression in GIST tumor tissue was detected by real-time polymerase chain reaction, and SLITRK3 protein levels were estimated by immunohistochemistry. The correlation of SLITRK3 expression with various tumor clinicopathological characteristics and follow-up data were analyzed.RESULTS: GIST tumors had high expression of SLITRK3 compared with adjacent normal tissues and the expression level gradually increased with risk grade. SLITRK3 protein expression was closely associated with gastrointestinal bleeding, tumor site, tumor size, mitotic index, and National Institutes of Health(NIH) classification. Survival analysis showed that SLITRK3 expression was closely correlated with overall survival and disease-free survival of GIST patients. Multivariate analysis also identified SLITRK3 expression, mitotic index, and NIH stage as significant risk factors of GIST recurrence.CONCLUSION: SLITRK3 expression is a highly significant predictor of GIST recurrence and metastasis. Combinations of SLITRK3 and NIH stage have strong predictive and prognostic value, and are feasible markers for clinical practice in gastrointestinal stromal tumor. AIM: To assess the influence of SLIT and NTRKlike family member 3(SLITRK3) on the prognosis of gastrointestinal stromal tumor(GIST) and determine whether SLITRK3 can help improve current risk stratification systems.METHODS: We hypothesized that SLITRK3 could be used as a prognostic molecular biomarker for GIST. 35 fresh tumor samples and 417 paraffin-embedded specimens from GIST patients were utilized. SLITRK3m RNA expression in GIST tumor tissue was detected by real-time polymerase chain reaction, and SLITRK3 protein levels were estimated by immunohistochemistry. The correlation of SLITRK3 expression with various tumor clinicopathological characteristics and follow-up data were analyzed.RESULTS: GIST tumors had high expression of SLITRK3 compared with adjacent normal tissues and the expression level gradually increased with risk grade. SLITRK3 protein expression was closely associated with gastrointestinal bleeding, tumor site, tumor size, mitotic index, and National Institutes of Health(NIH) classification. Survival analysis showed that SLITRK3 expression was closely correlated with overall survival and disease-free survival of GIST patients. Multivariate analysis also identified SLITRK3 expression, mitotic index, and NIH stage as significant risk factors of GIST recurrence.CONCLUSION: SLITRK3 expression is a highly significant predictor of GIST recurrence and metastasis. Combinations of SLITRK3 and NIH stage have strong predictive and prognostic value, and are feasible markers for clinical practice in gastrointestinal stromal tumor.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第27期8398-8407,共10页 世界胃肠病学杂志(英文版)
基金 Supported by National Natural Science Foundation of China General Program,No.81272743 Shanghai City Committee of Science and Technology Key Project,No.11411950800 Key Discipline Project of Renji Hospital,Shanghai Jiaotong University School of Medicine,No.RJ4101304
关键词 SLITRK3 GASTROINTESTINAL STROMAL tumor Biomarkers Non-epithelial TUMORS Risk STRATIFICATION SLITRK3 Gastrointestinal stromal tumor Biomarkers Non-epithelial tumors Risk stratification
  • 相关文献

参考文献32

  • 1Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, DortokA, Gustavsson B, Sablinska K, Kindblom LG. Gastrointestinalstromal tumors: the incidence, prevalence, clinical course, andprognostication in the preimatinib mesylate era--a populationbasedstudy in western Sweden. Cancer 2005; 103: 821-829 [PMID:15648083 DOI: 10.1002/cncr.20862].
  • 2Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG.Gastrointestinal stromal tumors in Iceland, 1990-2003: theicelandic GIST study, a population-based incidence and pathologicrisk stratification study. Int J Cancer 2005; 117: 289-293 [PMID:15900576 DOI: 10.1002/ijc.21167].
  • 3Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M,Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromaltumours is underestimated: results of a nation-wide study. Eur JCancer 2005; 41: 2868-2872 [PMID: 16293410 DOI: 10.1016/j.ejca.2005.09.009].
  • 4Rubio J, Marcos-Gragera R, Ortiz MR, Miro J, Vilardell L,Girones J, Hernandez-Yague X, Codina-Cazador A, Bernado L,Izquierdo A, Colomer R. Population-based incidence and survivalof gastrointestinal stromal tumours (GIST) in Girona, Spain. EurJ Cancer 2007; 43: 144-148 [PMID: 17055254 DOI: 10.1016/j.ejca.2006.07.015].
  • 5Hirota S. Gastrointestinal stromal tumors: their origin and cause.Int J Clin Oncol 2001; 6: 1-5 [PMID: 11706520].
  • 6Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, MakiRG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD,Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K,DeMatteo RP. Pathologic and molecular features correlate withlong-term outcome after adjuvant therapy of resected primary GIstromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 2014; 32:1563-1570 [PMID: 24638003 DOI: 10.1200/JCO.2013.51.2046].
  • 7Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H,Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, FisherGA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H,Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW,Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von MehrenM, Wayne JD, Zalcberg J. NCCN Task Force report: managementof patients with gastrointestinal stromal tumor (GIST)--update ofthe NCCN clinical practice guidelines. J Natl Compr Canc Netw2007; 5 Suppl 2: S1-S29; quiz S30 [PMID: 17624289].
  • 8Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, LongleyBJ, Miettinen M, O乫Leary TJ, Remotti H, Rubin BP, Shmookler B,Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors:A consensus approach. Hum Pathol 2002; 33: 459-465 [PMID:12094370].
  • 9Bumming P, Nilsson O, Ahlman H, Welbencer A, Andersson MK,Sjolund K, Nilsson B. Gastrointestinal stromal tumors regularlyexpress synaptic vesicle proteins: evidence of a neuroendocrinephenotype. Endocr Relat Cancer 2007; 14: 853-863 [PMID:17914114 DOI: 10.1677/ERC-06-0014].
  • 10Aruga J, Mikoshiba K. Identification and characterization ofSlitrk, a novel neuronal transmembrane protein family controllingneurite outgrowth. Mol Cell Neurosci 2003; 24: 117-129 [PMID:14550773].

同被引文献6

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部